Literature DB >> 11836392

Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.

Keith Meyer1, Arnab Basu, Craig T Przysiecki, L Martin Lagging, Adrian M Di Bisceglie, Anthony J Conley, Ranjit Ray.   

Abstract

We previously reported a number of features of hepatitis C virus (HCV) chimeric glycoproteins related to pseudotype virus entry into mammalian cells. In this study, pseudotype virus was neutralized by HCV E2 glycoprotein-specific antibodies and infected human sera. Neutralization (50% reduction of pseudotype virus plaque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at concentrations of between 2.5 and 10 microg/ml. A hyperimmune rabbit antiserum to an E2 hypervariable region 1 (HVR1) mimotope also exhibited an HCV E2 pseudotype virus neutralization titer of approximately 1/50. An E1 pseudotype virus used as a negative control was not neutralized to a significant level (<1/10) by these MAbs or rabbit antiserum to E2 HVR1. Since HCV probably has a lipid envelope, the role of complement in antibody-mediated virus neutralization was examined. Significant increases in the neutralization titers of the human MAbs (approximately 60- to 160-fold higher) and rabbit antiserum to HVR1 mimotopes (approximately 10-fold higher) were observed upon addition of guinea pig complement. Further, these studies suggested that complement activation occurred primarily by the classical pathway, since a deficiency in the C4 component led to a significant decrease in the level of virus neutralization. This same decrease was not observed with factor B-deficient complement. We also determined that 9 of 56 HCV-infected patient sera (16%) had detectable pseudotype virus neutralization activity at serum dilutions of between 1/20 and 1/50 and that complement addition enhanced the neutralization activity of some of the HCV-infected human sera. Taken together, these results suggest that during infection, HCV E2 glycoprotein induces a weak neutralizing antibody response, that those antibodies can be measured in vitro by the surrogate pseudotype virus plaque reduction assay, and that neutralization function can be augmented by complement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836392      PMCID: PMC153822          DOI: 10.1128/jvi.76.5.2150-2158.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

Review 2.  Complement and immunity to viruses.

Authors:  P J Lachmann; A Davies
Journal:  Immunol Rev       Date:  1997-10       Impact factor: 12.988

3.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

Authors:  E Kenny-Walsh
Journal:  N Engl J Med       Date:  1999-04-22       Impact factor: 91.245

4.  A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity.

Authors:  T Decker; M L Lohmann-Matthes
Journal:  J Immunol Methods       Date:  1988-11-25       Impact factor: 2.303

5.  Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum.

Authors:  X Fan; H Solomon; J E Poulos; B A Neuschwander-Tetri; A M Di Bisceglie
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

6.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

8.  Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants.

Authors:  G Puntoriero; A Meola; A Lahm; S Zucchelli; B B Ercole; R Tafi; M Pezzanera; M U Mondelli; R Cortese; A Tramontano; G Galfre'; A Nicosia
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

9.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.

Authors:  P Farci; H J Alter; D C Wong; R H Miller; S Govindarajan; R Engle; M Shapiro; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

10.  High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

Authors:  K Ishii; D Rosa; Y Watanabe; T Katayama; H Harada; C Wyatt; K Kiyosawa; H Aizaki; Y Matsuura; M Houghton; S Abrignani; T Miyamura
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

View more
  22 in total

1.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 2.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

3.  Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.

Authors:  Budhaditya Mazumdar; Arup Banerjee; Keith Meyer; Ranjit Ray
Journal:  Hepatology       Date:  2011-07-25       Impact factor: 17.425

4.  Transcriptional repression of C4 complement by hepatitis C virus proteins.

Authors:  Arup Banerjee; Budhaditya Mazumdar; Keith Meyer; Adrian M Di Bisceglie; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

5.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Authors:  Erin Mehlhop; Steevenson Nelson; Christiane A Jost; Sergey Gorlatov; Syd Johnson; Daved H Fremont; Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

7.  Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells.

Authors:  Arnab Basu; Tatsuo Kanda; Aster Beyene; Kousuke Saito; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

8.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

9.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever.

Authors:  Juan D Rodas; Igor S Lukashevich; Juan C Zapata; Cristiana Cairo; Ilia Tikhonov; Mahmoud Djavani; C David Pauza; Maria S Salvato
Journal:  J Med Virol       Date:  2004-03       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.